COMMUNIQUÉS West-GlobeNewswire

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
29/01/2026
Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Review Preliminary data from Phase 1/2 study of DNL126 [...]
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
29/01/2026
MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
29/01/2026
Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3% Income from operations increased 18%; non-GAAP income from [...]
Picard Medical / SynCardia to Present Webinar on the Emperor Fully Implantable Total Artificial Heart Hosted by DeviceTalks
29/01/2026
TUCSON, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved [...]
Lexicon Announces Proposed Public Offering of Common Stock
29/01/2026
THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced that it has commenced an underwritten public offering to offer and sell, subject to [...]
BioSyent Declares First Quarter 2026 Dividend
29/01/2026
MISSISSAUGA, Ontario, Jan. 29, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per [...]
Clover Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
29/01/2026
WILMINGTON, Del., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the [...]
Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
29/01/2026
GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
Focus ADHD Expands Online Psychiatric Services to Adults Across Iowa
29/01/2026
DES MOINES, Iowa, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Focus ADHD, a premier online psychiatric clinic specializing in adult ADHD treatment, today announced the expansion of its telehealth services to patients throughout [...]
Option Care Health to Participate in the TD Cowen Healthcare Conference
29/01/2026
BANNOCKBURN, Ill., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will [...]
Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth
29/01/2026
Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant Initiative expected to deliver approximately $3 million in cost savings in 2027 and $4 million in [...]
CareMed Has Been Selected as a National Specialty Pharmacy Provider for Exdensur (depemokimab-ulaa)
29/01/2026
NEW HYDE PARK, N.Y., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by GSK for Exdensur (depemokimab), indicated for the add-on maintenance [...]
XTL Update on Recent Developments
29/01/2026
RAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “ Company ” or “ XTL ”), announced that it is working diligently to close the acquisition of 85% of the [...]
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
29/01/2026
JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevance SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE [...]
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
29/01/2026
mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established global rare disease [...]
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer
29/01/2026
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER THIS POSITIVE DECISION FROM THE USA PATENT OFFICE [...]
Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue
29/01/2026
WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that the current time- and individual performance-based long-term stock incentive [...]
Ardena completes divestment of its Södertälje drug substance site in Sweden to Nanologica
29/01/2026
Ghent, Belgium, 29th January 2026 – Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, today announced that it has completed the divestment of its drug substance ( [...]
AB Science reçoit un avis d'autorisation pour un brevet américain couvrant le masitinib dans le traitement du cancer de la prostate métastatique hormono-resistant
29/01/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE REÇOIT UN AVIS D'AUTORISATION POUR UN BREVET AMÉRICAIN COUVRANT LE MASITINIB DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RESISTANT CETTE DÉCISION FAVORABLE DE L’ [...]

Pages